🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  2. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  3. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  4. LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa Dystrophica

    phase 2 mab completed

    1 trial

  5. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  6. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  7. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 small molecule active

    1 trial

  8. Leukine, OXALIPLATIN, ENDOXAN 50 mg, comprimé enrobé, STC-1010, FLUOROURACIL, CALCIUM FOLINATE

    Lacuna Pharma Pty Ltd

    Unresectable locally advanced or metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  9. LiPlaCis

    Allarity Therapeutics

    Phase 1: Advanced or Refractory Solid Tumours

    phase 2 small molecule completed

    1 trial

  10. Lidocaína B. Braun 20 mg/ml solución inyectable, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio

    The George Institute

    headache pain related to SAH, Spontaneous subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  11. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

    phase 2 small molecule active

    1 trial

  12. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  13. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  14. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  15. Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD

    Mineralys Therapeutics

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  16. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

  17. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  18. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  19. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule completed

    1 trial

  20. METHYLPREDNISOLONE, METHYLPREDNISOLONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  21. METRONIDAZOLE, FOSFOMYCIN, MOLGRAMOSTIM

    Lacuna Pharma Pty Ltd

    Pouchitis

    phase 2 small molecule active

    1 trial

  22. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  23. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  24. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources